WCLC

WCLC 2018 Toronto

English

Mandarin

Japanese

Expert interviews at WCLC 2018

 

Click on the button to load the content from playout.3qsdn.com.

Load content

Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.

Click on the button to load the content from playout.3qsdn.com.

Load content

James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.

Click on the button to load the content from playout.3qsdn.com.

Load content

Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.

Click on the button to load the content from playout.3qsdn.com.

Load content

Vera Hirsh discusses the latest clinical achievements using EGFR-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.

Click on the button to load the content from playout.3qsdn.com.

Load content

Virote Sriuranpong talks about new agents in the area of EGFR-targeted therapy as well as the results obtained with afatinib in a named patient program at Asian centers.


English

Mandarin

Japanese

Expert interviews at WCLC

Click on the button to load the content from playout.3qsdn.com.

Load content

IASLC 18th WCLC 2017, Yokohama
Prof. David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.

Click on the button to load the content from playout.3qsdn.com.

Load content

IASLC 18th WCLC 2017, Yokohama
Prof. Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.

Click on the button to load the content from playout.3qsdn.com.

Load content

IASLC 18th WCLC 2017, Yokohama
Prof. Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.

Click on the button to load the content from playout.3qsdn.com.

Load content

IASLC 18th WCLC 2017, Yokohama
Prof. Paul A. Bunn discusses current and future treatment options in lung cancer.


WCLC 2016

English

Spanish

Japanese

Mandarin

Expert interviews at WCLC

Click on the button to load the content from playout.3qsdn.com.

Load content

Martin Schuler on the current state-of-play for EGFR diagnostic technologies

Click on the button to load the content from playout.3qsdn.com.

Load content

Johan Vansteenkiste discusses the practical considerations for immunotherapy

Click on the button to load the content from playout.3qsdn.com.

Load content

Robert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress

Click on the button to load the content from playout.3qsdn.com.

Load content

Fiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer

Click on the button to load the content from playout.3qsdn.com.

Load content

James Chih-Hsin Yang talks TKIs